SCHEMBL4576186

SCHEMBL4576186

C=CCN1C[C@H](C)N([C@@H](c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)C[C@H]1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 1.00
OPRD1 P41143 5/20 1.00
CYP1A2 P05177 4/20 1.00
CYP2C9 P11712 3/20 1.00
HPGD P15428 3/20 1.00
KDM4E B2RXH2 2/20 1.00
CYP2C19 P33261 2/20 1.00
OPRM1 P35372 2/20 0.83
OPRK1 P41145 2/20 0.83
SIGMAR1 Q99720 1/20 0.83
MEN1 O00255 2/20 0.79
KMT2A Q03164 2/20 0.79
CYP2D6 P10635 2/20 0.79
LMNA P02545 1/20 0.79
BLM P54132 1/20 0.79
PMP22 Q01453 1/20 0.79
MAPT P10636 1/20 0.79
TDP1 Q9NUW8 1/20 0.79
NFKB1 P19838 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29457716 1.00 CYP3A4 (1.00) CYP3A4OPRD1CYP1A2CYP2C9HPGD
SCHEMBL12018004 1.00 CYP3A4 (1.00) CYP3A4OPRD1CYP1A2CYP2C9HPGD
SCHEMBL14343894 1.00 CYP3A4 (1.00) CYP3A4OPRD1CYP1A2CYP2C9HPGD
SCHEMBL3265985 0.92 CYP3A4 (0.85) CYP3A4OPRD1CYP1A2CYP2C9HPGD
SCHEMBL4586159 0.91 CYP3A4 (0.84) CYP3A4OPRD1CYP1A2CYP2C9HPGD
SCHEMBL2750833 0.91 CYP3A4 (0.84) CYP3A4OPRD1CYP1A2CYP2C9HPGD
SCHEMBL232128 0.91 CYP3A4 (1.00) CYP3A4OPRD1CYP1A2CYP2C9HPGD
SCHEMBL4576328 0.91 CYP3A4 (1.00) CYP3A4OPRD1CYP1A2CYP2C9HPGD
SCHEMBL232384 0.91 CYP3A4 (1.00) CYP3A4OPRD1CYP1A2CYP2C9HPGD
SCHEMBL12019442 0.91 CYP3A4 (1.00) CYP3A4OPRD1CYP1A2CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220601-A1 DELTA OPIOID RECEPTOR AGONIST COMPOUNDS VERSI GROUP, LLC 2012-08-30 US claimed
US-20070173515-A1 DELTA OPIOID RECEPTOR AGONIST COMPOUNDS MOUNT COOK BIOSCIENCES, INC. (US) 2007-07-26 US claimed
US-12584916-B2 Method for measuring the modulation of the activation of a G protein-coupled receptor with GTP analogues CISBIO BIOASSAYS (FR) 2026-03-24 US disclosed
US-12522656-B2 Anti-G-protein alpha antibody CISBIO BIOASSAYS (FR) 2026-01-13 US disclosed
US-20250376477-A1 ANALGESIC DELTA OPIOID RECEPTOR BITOPIC LIGANDS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2025-12-11 US disclosed
EP-3658913-B1 METHOD FOR MEASURING MODULATION IN THE ACTIVITY OF A G PROTEIN-COUPLED RECEPTOR CISBIO BIOASSAYS (FR) 2024-04-03 EP disclosed
WO-2024006977-A1 ANALGESIC DELTA OPIOID RECEPTOR BITOPIC LIGANDS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2024-01-04 WO disclosed
CN-111164427-B Method for measuring modulation of G protein coupled receptor activity CISBIO生物试验公司 2023-12-19 CN disclosed
CN-116987031-A Single benzyl isoquinoline alkaloid, preparation method and application thereof, and pharmaceutical composition 中国科学院大连化学物理研究所 2023-11-03 CN disclosed
CN-114539242-B Protoberberine-stephania tetrandra alkaloid dimer and application and preparation thereof 中国科学院大连化学物理研究所 2023-05-30 CN disclosed
US-20230135945-A1 Method for Measuring Modulation in the Activity of a G Protein-Coupled Receptor CISBIO ASSAYS (FR) 2023-05-04 US disclosed
EP-1469850-A1 METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS Ardent Pharmaceuticals, Inc. (US) 2004-10-27 EP disclosed
EP-1450807-A1 METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS Ardent Pharmaceuticals, Inc. (US) 2004-09-01 EP disclosed
WO-2003057223-A9 METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS ARDENT PHARMACEUTICALS INC (US) 2004-04-29 WO disclosed
US-20040002503-A1 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists VERSI GROUP, LLC 2004-01-01 US disclosed
WO-2003094853-A2 COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS ARDENT PHARMACEUTICALS, INC. (US) 2003-11-20 WO disclosed
US-20030186872-A1 Method of treating sexual dysfunctions with delta opioid receptor agonist compounds DMK PHARMACEUTICALS CORPORATION 2003-10-02 US disclosed
US-20030144299-A1 Method of treating depression with delta receptor agonist compounds DMK PHARMACEUTICALS CORPORATION 2003-07-31 US disclosed
WO-2003057223-A1 METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS ARDENT PHARMACEUTICALS, INC. (US) 2003-07-17 WO disclosed
WO-2003037342-A1 METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS ARDENT PHARMACEUTICALS, INC. (US) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376477-A1 ANALGESIC DELTA OPIOID RECEPTOR BITOPIC LIGANDS OPRD1, OPRK1, OPRM1 CYP3A4 273/4885OPRD1 1/4885CYP1A2 121/4885
US-20030144299-A1 Method of treating depression with delta receptor agonist compounds CHRND, CHRNE, CHRNA3 CYP3A4 3126/4885OPRD1 9/4885CYP1A2 2383/4885
US-20030186872-A1 Method of treating sexual dysfunctions with delta opioid receptor agonist compounds OPRD1, OPRK1, OPRM1 CYP3A4 804/4885OPRD1 1/4885CYP1A2 656/4885
US-12584916-B2 Method for measuring the modulation of the activation of a G protein-coupled receptor with GTP analogues GNAI1, GNAI3, GNB1 CYP3A4 4714/4885OPRD1 461/4885CYP1A2 4813/4885
US-20070173515-A1 DELTA OPIOID RECEPTOR AGONIST COMPOUNDS OPRD1, OPRM1, OPRK1 CYP3A4 675/4885OPRD1 1/4885CYP1A2 760/4885
US-20040002503-A1 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists OPRD1, OPRK1, OPRM1 CYP3A4 1595/4885OPRD1 1/4885CYP1A2 688/4885
US-20120220601-A1 DELTA OPIOID RECEPTOR AGONIST COMPOUNDS OPRD1, OPRM1, OPRK1 CYP3A4 675/4885OPRD1 1/4885CYP1A2 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.